Pharma BD Deal Intelligence
A $1.65B all-cash acquisition that collapsed into a $685.7M goodwill writeoff within 13 months. Hologic's move into medical aesthetics with Cynosure was sold off just three years later for $205M, recovering roughly 9-12% of the original price.
Hologic paid $1.65B for Cynosure in 2017, wrote off $685.7M in goodwill within 13 months, and sold the business for $205M (net ~$142M cash) in 2019 — one of the clearest failed diversifications in recent medtech M&A history.
Full analysis, sources & comparables →Hologic moves into aesthetics market with $1.65B purchase of Cynosure, betting that women's-health channel synergies will unlock MonaLisa Touch in the OB/GYN…
Hologic announces sale of Cynosure to CD&R for $205M in cash with an additional pre-tax impairment charge of $155-185M, formalizing the strategic retreat from…
Hologic unloads underperforming Cynosure medical aesthetics unit to Clayton, Dubilier & Rice for $205M after a $732M writedown in 2018 — completing one of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Hologic agreed to acquire Cynosure for $66.00/share in cash, equity value approximately $1.65B (enterprise value $1.44B net of cash). The acquisition extended Hologic's diagnostics-led women's health franchise into medical aesthetics, including the MonaLisa Touch system for vaginal health. Acquisition completed March 22, 2017.
Hologic paid $1.65B for Cynosure in 2017, wrote off $685.7M in goodwill within 13 months, and sold the business for $205M (net ~$142M cash) in 2019 — one of the clearest failed diversifications in recent medtech M&A history.
Assessment window: 5yr post-close.
$1.6B Hologic-Cynosure deal equity value (Feb 2017)
Medical aesthetics covers cash-pay, physician-administered procedures including laser hair removal, body contouring (SculpSure), tattoo removal (PicoSure), skin pigmentation, and women's health (MonaLisa Touch CO2 laser for vaginal atrophy). The category is consumer-discretionary and elective, with demand sensitive to consumer credit and disposable income.
In 2017 the aesthetic laser device market was led by Cynosure, Lumenis, Cutera, Alma Lasers, Sciton, and Solta Medical (Bausch Health), with Allergan dominating adjacent injectables (Botox, Juvederm) rather than energy devices. Cynosure's PicoSure (picosecond laser for tattoo and pigmentation), SculpSure (non-invasive body contouring vs Allergan's CoolSculpting), and MonaLisa Touch (vaginal CO2 laser) were positioned as differentiated platforms. Hologic's strategic thesis was to leverage its OB/GYN channel access for MonaLisa Touch and other women's-health-adjacent devices. The thesis failed almost immediately. BTIG analyst Sean Lavin had flagged channel-leverage skepticism at announcement. FDA warnings on energy-based vaginal devices (July 2018) gutted the MonaLisa Touch thesis. Hologic took a $732M Cynosure writedown in 2018 and ultimately sold the business to Clayton, Dubilier & Rice for $205M in November 2019 — a >$1.4B value destruction in 2.5 years, making this one of the worst medtech acquisitions of the decade.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hologic, Inc. / Cynosure, Inc. (this deal) | 2017 | $1.6B | 12 |
| Hologic, Inc. / Gen-Probe Incorporated | 2012 | $3.8B | 78 |
| Hologic, Inc. / Third Wave Technologies, Inc. | 2008 | $580M | 36 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
← Browse all deals · How we score deals
More: 2017 deals · Hologic, Inc. deals · Dermatology deals